We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more
Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug...
In Monday’s pre-market trading, U.S. index futures are mixed, with Wall Street in anticipation of the monetary policy guidelines that the Federal Reserve is expected to release during the...
LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and other...
Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company...
Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of a fireside chat by HCW’s...
The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments, greater precision in clinical development, and improved combination regimens with the...
Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.54 | -20.5059920107 | 7.51 | 8.27 | 5.82 | 250944 | 6.92479221 | CS |
| 4 | -3.23 | -35.1086956522 | 9.2 | 11.99 | 5.82 | 357160 | 8.4635946 | CS |
| 12 | 1.73 | 40.8018867925 | 4.24 | 11.99 | 3.85 | 320468 | 7.44469269 | CS |
| 26 | 2.67 | 80.9090909091 | 3.3 | 11.99 | 2.38 | 171824 | 6.94985305 | CS |
| 52 | 0.89 | 17.5196850394 | 5.08 | 11.99 | 2.38 | 103285 | 6.60704984 | CS |
| 156 | -9.77 | -62.0711562897 | 15.74 | 16.945 | 2.38 | 70006 | 7.8341857 | CS |
| 260 | -9.19 | -60.6200527704 | 15.16 | 24.84 | 2.38 | 75514 | 10.28380964 | CS |
Monksdream
3 weeks ago
dinogreeves
4 weeks ago
dinogreeves
4 weeks ago
spartex
4 weeks ago
Monksdream
4 weeks ago
dinogreeves
4 weeks ago
Monksdream
4 weeks ago
dinogreeves
4 weeks ago
dinogreeves
1 month ago
dinogreeves
1 month ago
Tremors!
1 month ago
Roily23
1 month ago
Roily23
1 month ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
